ES2081857T3 - Nuevos inhibidores de alpha-glucosidasa. - Google Patents

Nuevos inhibidores de alpha-glucosidasa.

Info

Publication number
ES2081857T3
ES2081857T3 ES89401227T ES89401227T ES2081857T3 ES 2081857 T3 ES2081857 T3 ES 2081857T3 ES 89401227 T ES89401227 T ES 89401227T ES 89401227 T ES89401227 T ES 89401227T ES 2081857 T3 ES2081857 T3 ES 2081857T3
Authority
ES
Spain
Prior art keywords
glucosidase inhibitors
new alpha
new
employment
alpha
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES89401227T
Other languages
English (en)
Inventor
Jean-Bernard Ducep
Charles Danzin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Merrell Dow Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrell Dow Pharmaceuticals Inc filed Critical Merrell Dow Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2081857T3 publication Critical patent/ES2081857T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/12—Acyclic radicals, not substituted by cyclic structures attached to a nitrogen atom of the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/048—Pyridine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/06—Heterocyclic radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

ESTA INVENCION SE REFIERE A NUEVOS N - DERIVADOS DE 1 - DESOXI -NOJIRIMICINA, A PROCESOS PARA SU PREPARACION Y A SUS APLICACIONES DE EMPLEO FINAL, PARTICULARMENTE A SU EMPLEO EN EL TRATAMIENTO DE LA DIABETES.
ES89401227T 1988-06-02 1989-04-28 Nuevos inhibidores de alpha-glucosidasa. Expired - Lifetime ES2081857T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP88401340A EP0344383A1 (en) 1988-06-02 1988-06-02 Novel alpha-Glucosidase inhibitors

Publications (1)

Publication Number Publication Date
ES2081857T3 true ES2081857T3 (es) 1996-03-16

Family

ID=8200392

Family Applications (1)

Application Number Title Priority Date Filing Date
ES89401227T Expired - Lifetime ES2081857T3 (es) 1988-06-02 1989-04-28 Nuevos inhibidores de alpha-glucosidasa.

Country Status (22)

Country Link
US (1) US5157116A (es)
EP (1) EP0344383A1 (es)
JP (1) JP2791419B2 (es)
KR (1) KR0155541B1 (es)
CN (1) CN1023803C (es)
AR (1) AR247890A1 (es)
AT (1) ATE129716T1 (es)
AU (1) AU608711B2 (es)
CA (1) CA1339740C (es)
DE (1) DE68924670T2 (es)
DK (1) DK267489A (es)
ES (1) ES2081857T3 (es)
FI (1) FI92934C (es)
GR (1) GR3018354T3 (es)
HU (1) HU203559B (es)
IE (1) IE68455B1 (es)
IL (1) IL90463A0 (es)
NO (1) NO170023C (es)
NZ (1) NZ229337A (es)
PH (1) PH25908A (es)
PT (1) PT90713B (es)
ZA (1) ZA894068B (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3936295A1 (de) * 1989-11-01 1991-05-02 Bayer Ag Verfahren zur herstellung von zwischenprodukten und zur synthese von n-(2-hydroxyethyl)-2-hydroxymethyl-3,4,5-trihydroxypiperidine
US5504078A (en) * 1990-06-08 1996-04-02 Merrell Dow Pharmaceuticals Inc. α-glucosidase inhibitors
US5844102A (en) * 1994-07-07 1998-12-01 University Of Maryland Baltimore County Glycohydrolase inhibitors, their preparation and use thereof
JP3580900B2 (ja) * 1995-04-20 2004-10-27 ホクレン農業協同組合連合会 α−グルコシダーゼ阻害剤を含む糖を主体とする組成物を有効成分とする食品及び飼料
US5981720A (en) * 1996-09-09 1999-11-09 Wisconsin Alumni Res Found Human salivary proteins and fragments thereof having alpha-glucosidase inhibitory activity
ATE422359T1 (de) * 1997-04-15 2009-02-15 Csir Verbindungen und pharmazeutische zusammensetzungen mit appetitunterdrückender aktivität
WO1998050359A1 (en) * 1997-05-06 1998-11-12 Novo Nordisk A/S Novel heterocyclic compounds
GB2396815B (en) * 1999-10-27 2004-09-08 Phytopharm Plc A composition comprising a pregnenone derivative and an NSAID
GB2363985B (en) 2000-06-30 2004-09-29 Phytopharm Plc Extracts,compounds & pharmaceutical compositions having anti-diabetic activity and their use
JP4486792B2 (ja) * 2003-06-12 2010-06-23 学校法人近畿大学 環状オニウム化合物およびグルコシダーゼ阻害剤
US7262318B2 (en) * 2004-03-10 2007-08-28 Pfizer, Inc. Substituted heteroaryl- and phenylsulfamoyl compounds
US20060025449A1 (en) * 2004-03-25 2006-02-02 United Therapeutics Use of N-substituted imino sugars for appetite suppression
US20050288340A1 (en) * 2004-06-29 2005-12-29 Pfizer Inc Substituted heteroaryl- and phenylsulfamoyl compounds
AU2005308575A1 (en) * 2004-11-23 2006-06-01 Warner-Lambert Company Llc 7-(2h-pyrazol-3-yl)-3, 5-dihyroxy-heptanoic acid derivatives as HMG Co-A reductase inhibitors for the treatment of lipidemia
WO2006133447A1 (en) * 2005-06-08 2006-12-14 Amicus Therapeutics, Inc. Crystalline sugar compositions and method of making
US20060293508A1 (en) * 2005-06-08 2006-12-28 Michael Major Stabilization of triflated compounds
US7973157B2 (en) * 2005-06-08 2011-07-05 Amicus Therapeutics, Inc. Imino and amino sugar purification
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
GB0614947D0 (en) * 2006-07-27 2006-09-06 Isis Innovation Epitope reduction therapy
JP5498168B2 (ja) 2006-12-01 2014-05-21 ブリストル−マイヤーズ スクイブ カンパニー アテローム性動脈硬化および循環器疾患の治療のためのｃｅｔｐ阻害剤としてのｎ−（（３−ベンジル）−２，２−（ビス−フェニル）−プロパン−１−アミン誘導体
ATE518544T1 (de) 2007-03-12 2011-08-15 Zadec Aps Rotbusch-extrakt gegen diabetes
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
MX2009013293A (es) 2007-06-04 2010-02-15 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos.
EP2810951B1 (en) 2008-06-04 2017-03-15 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
CA2730603C (en) 2008-07-16 2019-09-24 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
CA2799708A1 (en) 2010-05-21 2011-11-24 Pfizer Inc. 2-phenyl benzoylamides
US20130156720A1 (en) 2010-08-27 2013-06-20 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
CA2828343A1 (en) 2011-03-04 2012-09-13 The Scripps Research Institute Edn3-like peptides and uses thereof
MY188344A (en) 2012-03-09 2021-12-01 Biotropics Malaysia Berhad Extract formulations of rhodamnia cinerea and uses thereof
JP2016514670A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド 他の薬物と組み合わせたグアニル酸シクラーゼ受容体アゴニスト
JP2016514671A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼのアゴニストおよびその使用
SG11201507496UA (en) 2013-04-17 2015-11-27 Pfizer N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases
EA201592263A1 (ru) 2013-06-05 2016-05-31 Синерджи Фармасьютикалз, Инк. Ультрачистые агонисты гуанилатциклазы c, способ их получения и использования
EP3186242B1 (en) 2014-08-29 2021-10-06 Tes Pharma S.r.l. Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
AU2017342083A1 (en) 2016-10-14 2019-04-11 Tes Pharma S.R.L. Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
AR117122A1 (es) 2018-11-20 2021-07-14 Tes Pharma S R L INHIBIDORES DE LA ÁCIDO a-AMINO-b-CARBOXIMUCÓNICO SEMIALDEHÍDO DESCARBOXILASA
US11248001B2 (en) 2019-01-18 2022-02-15 Astrazeneca Ab PCSK9 inhibitors and methods of use thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1555654A (en) * 1977-06-25 1979-11-14 Exxon Research Engineering Co Agricultural burner apparatus
NO154918C (no) * 1977-08-27 1987-01-14 Bayer Ag Analogifremgangsmaate til fremstilling av terapeutisk aktive derivater av 3,4,5-trihydroksypiperidin.
DE2830469A1 (de) * 1978-07-11 1980-01-24 Bayer Ag Herstellung von l-desoxy-nojirimycin und n-substituierten derivaten
DE2922760A1 (de) * 1979-06-05 1980-12-11 Bayer Ag Neue derivate von 3,4,5-trihydroxypiperidin, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel sowie in der tierernaehrung
GB2064527B (en) * 1979-12-08 1984-05-02 Nippon Shinyaku Co Ltd Moranoline derivatives and process for preparation thereof
DE3038901A1 (de) * 1980-10-15 1982-05-06 Bayer Ag, 5090 Leverkusen Verfahren zur herstellung von n-substituierten derivaten des 1-desoxynojirimycins
JPS61115093A (ja) * 1984-11-09 1986-06-02 Nippon Shinyaku Co Ltd モラノリン誘導体の製法
US4634765A (en) * 1984-12-18 1987-01-06 Merrell Dow Pharmaceuticals Inc. Homodisaccharide hypoglycemic agents
GB2181729B (en) * 1985-10-12 1990-04-04 Nippon Shinyaku Co Ltd Glucosylmoranoline derivatives and production thereof
DE3737523A1 (de) * 1987-11-05 1989-05-18 Bayer Ag Verwendung von substituierten hydroxypiperidinen als antivirale mittel

Also Published As

Publication number Publication date
ATE129716T1 (de) 1995-11-15
NO170023B (no) 1992-05-25
IE891798L (en) 1989-12-02
NO892230D0 (no) 1989-06-01
AR247890A1 (es) 1995-04-28
IE68455B1 (en) 1996-06-26
DK267489D0 (da) 1989-06-01
JP2791419B2 (ja) 1998-08-27
GR3018354T3 (en) 1996-03-31
DK267489A (da) 1989-12-03
NO170023C (no) 1992-09-02
DE68924670T2 (de) 1996-05-23
FI92934C (fi) 1995-01-25
AU608711B2 (en) 1991-04-11
FI892682A0 (fi) 1989-06-01
US5157116A (en) 1992-10-20
CA1339740C (en) 1998-03-17
FI92934B (fi) 1994-10-14
PH25908A (en) 1991-12-19
NO892230L (no) 1989-12-04
KR0155541B1 (ko) 1998-10-15
HU203559B (en) 1991-08-28
CN1040032A (zh) 1990-02-28
EP0344383A1 (en) 1989-12-06
HUT50191A (en) 1989-12-28
PT90713A (pt) 1989-12-29
JPH0225498A (ja) 1990-01-26
IL90463A0 (en) 1990-01-18
AU3580189A (en) 1990-02-01
FI892682L (fi) 1989-12-03
ZA894068B (en) 1990-09-26
PT90713B (pt) 1993-09-30
NZ229337A (en) 1990-12-21
DE68924670D1 (de) 1995-12-07
KR910000776A (ko) 1991-01-30
CN1023803C (zh) 1994-02-16

Similar Documents

Publication Publication Date Title
SE9802729D0 (sv) Novel Compounds
AR004357A1 (es) Compuestos de 1-fenil-2-dimetilaminometil-ciclohexan-1-ol, y procedimiento de preparacion para dichos compuestos.
FI893962A7 (fi) HIV-proteaasi-inhibiittoreita, jotka ovat hyödyllisiä AIDS:in hoidossa
ES2055587T3 (es) El uso de agonistas selectivos de gaba-b como agentes antitusivos.
MY102365A (en) Di-t-butylphenol compounds.
IE891798L (en) Novel ó-glucosidase inhibitors
MX9207449A (es) Inhibidores de la enzima proteolitica derivada de sacarina.
ES551319A0 (es) Un aparato para producir clinker de cemento blanco (como divisional de la solicitud de patente de invencion num. 544.021, presentada el 10.06.1985)
GT199800177A (es) Combinacion eficaz para el tratamiento de la impotencia .
DK0457849T3 (da) Klæbemiddel til elektrotransport
MX9704037A (es) 1,1-dioxidos de 1,2,5-tiadiazolidin-3-ona 2-substituida y composiciones y metodo de uso de los mismos.
ES2051695T3 (es) Tratamiento de la trombosis que contiene un fibrinolitico y un analogo de carbaciclina.
ES2078904T3 (es) Nuevos derivados de neplanocina.
MX9403032A (es) Quinolil-dihidropiridinas condensadas, procedimiento para su fabricacion ysu uso en medicamentos.
ATE28188T1 (de) Antikonvulsive mittel.
ES2058349T3 (es) Utilizacion de betabloqueadores para el tratamiento de la progresion de la miopia axial infantil.
ES2070134T3 (es) Inhibidores de lisil oxidasa.
EA199900579A1 (ru) Применение ингибиторов комт для производства лекарственного средства для профилактики сосудистых дисфункций при диабете
AU7028798A (en) Use of 2-methylthiazolidine-2,4-dicarboxylic acid as mucolytic agent
AU580890B2 (en) P-acylaminobenzamides
ES2156877T3 (es) Anilidas de acidos cicloalquilcarboxilicos.
DE3777359D1 (de) Aminosaeuresequenz des menschlichen alpha 2-plasmininhibitors und cdns sowie diese aminosaeuresequenz codierende genomische dns.
ES8801624A1 (es) Procedimiento para preparar disulfuros heterociclicos
ES2167942T3 (es) Empleo de 2-aminotetralinas 6,7-sustituidas apropiadas para la preparacion de una composicion farmaceutica para el tratamiento terapeutico de patologias inflamatorias y/o autoinmunes.
ES2161698T3 (es) Anticuerpos especificos contra plaquetas activadas, su produccion y su utilizacion en la diagnosis y terapia.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 345104

Country of ref document: ES